Avastin misses key data point in brain cancer study - geo.tv
HEALTH AWARENESS:
Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the cHompany said on Saturday.
- A.R.Shams's Reflection - Press and Online Publications.arshamssreflection.blogspot.com
HEALTH AWARENESS:
Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the cHompany said on Saturday.
- A.R.Shams's Reflection - Press and Online Publications.arshamssreflection.blogspot.com
No comments:
Post a Comment